Temporal Trends in the Epidemiology of HIV in Turkey

Author(s): F.S. Erdinc*, B. Dokuzoguz, S. Unal, S. Komur, A.C. Inkaya, D. Inan, I. Karaoglan, A. Deveci, M.K. Celen, S. Kose, N. Erben, G.C. Senturk, Y. Heper, S.S. Kutlu, C.A. Hatipoglu, S. Sumer, B. Kandemir, F. Sirmatel, Y. Bayindir, E. Yilmaz, Y. Ersoy, E. Kazak, M.T. Yildirmak, B. Kayaaslan, K. Ozden, A. Sener, A. Kara, O. Gunal, S. Birengel, A. Akbulut, F. Yetkin, N.O. Cuvalci, F. Sargin, H. Pullukcu, D. Gökengin, Multicentric HIV Study Group

Journal Name: Current HIV Research

Volume 18 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: The aim of this study was to analyze the temporal trends of HIV epidemiology in Turkey from 2011 to 2016.

Methods: Thirty-four teams from 28 centers at 17 different cities participated in this retrospective study. Participating centers were asked to complete a structured form containing questions about epidemiologic, demographic and clinical characteristics of patients presented with new HIV diagnosis between 2011 and 2016. Demographic data from all centers (complete or partial) were included in the analyses. For the cascade of care analysis, 15 centers that provided full data from 2011 to 2016 were included. Overall and annual distributions of the data were calculated as percentages and the Chi square test was used to determine temporal changes.

Results: A total of 2,953 patients between 2011 and 2016 were included. Overall male to female ratio was 5:1 with a significant increase in the number of male cases from 2011 to 2016 (p<0.001). The highest prevalence was among those aged 25-34 years followed by the 35-44 age bracket. The most common reason for HIV testing was illness (35%). While the frequency of sex among men who have sex with men increased from 16% to 30.6% (p<0.001) over the study period, heterosexual intercourse (53%) was found to be the most common transmission route. Overall, 29% of the cases presented with a CD4 count of >500 cells/mm3 while 46.7% presented with a CD4 T cell count of <350 cells/mm3. Among newly diagnosed cases, 79% were retained in care, and all such cases initiated ART with 73% achieving viral suppression after six months of antiretroviral therapy.

Conclusion: The epidemiologic profile of HIV infected individuals is changing rapidly in Turkey with an increasing trend in the number of newly diagnosed people disclosing themselves as MSM. New diagnoses were mostly at a young age. The late diagnosis was found to be a challenging issue. Despite the unavailability of data for the first 90, Turkey is close to the last two steps of 90-90-90 targets.

Keywords: HIV, AIDS, Epidemiology, Co-infection, diagnosis, fatality, HBV, HCV.

[2]
Gökengin D, Oprea C, Uysal S, Begovac J. The growing HIV epidemic in Central Europe: a neglected issue? J Virus Erad 2016; 2(3): 156-61.
[PMID: 27482455]
[3]
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2019 – 2018 data. Stockholm. Available at: https://www. ecdc.europa.eu/en/publications-data/hivaids-surveillance-europe-2019-2018-data
[4]
Republic of Turkey MoH, General Directorate of Public Health, HIV/AIDS Statistics report 2019.Available at: . https://hsgm.saglik.gov.tr/tr/bulasici-hastaliklar/hiv-aids/hiv-aids-liste/h%C4%B1v-aids-istatislik.htmlAccessed
[5]
Celikbas A, Ergonul O, Baykam N, et al. Epidemiologic and clinical characteristics of HIV/AIDS patients in Turkey, where the prevalence is the lowest in the region. J Int Assoc Physicians AIDS Care (Chic) 2008; 7(1): 42-5.
[http://dx.doi.org/10.1177/1545109707306575] [PMID: 17989428]
[6]
Gülümser Ç, Erbaydar T. HIV/AIDS epidemic in Turkey and use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Turk J Obstet Gynecol 2015; 12(4): 192-8.
[http://dx.doi.org/10.4274/tjod.52128] [PMID: 28913068]
[7]
Hekimoglu CHLD, Bilgin AC. Bibliometric investigation of epidemiologic studies in HIV positive individuals in Turkey. Turk J Public Health 2017; 15: 1-25.
[8]
Yemisen M, Aydın OA, Gunduz A, et al. Epidemiological profile of naive HIV-1/AIDS patients in Istanbul: the largest case series from Turkey. Curr HIV Res 2014; 12(1): 60-4.
[http://dx.doi.org/10.2174/1570162X12666140411111803] [PMID: 24725060]
[9]
Çerçi P, İnkaya AC, Alp Ş, Tümer A, Ünal S. Evaluation of 255 HIV/AIDS cases: Hacettepe cohort, Ankara, Turkey. Mikrobiyol Bul 2016; 50(1): 94-103.
[http://dx.doi.org/10.5578/mb.10610] [PMID: 27058333]
[10]
Antinori A, Coenen T, Costagiola D, et al. European Late Presenter Consensus Working Group. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12(1): 61-4.
[http://dx.doi.org/10.1111/j.1468-1293.2010.00857.x] [PMID: 20561080]
[11]
Berktas M, Unal S. Estimating the number of adults living with HIV infection in Turkey. Proceedings of the HIV/AIDS Congress; November 2017; Antalya, Turkey 2017.Available from:. http://hivaids2017.org/bildiriozetleri.pdf
[12]
Sayan MBI, Sanlıdag T, Kaymakamzade B, Sa’ad FT, Hıncal E. (A): HIV/AIDS dynamics between the years 1985-2016. Proceedings of the HIV/AIDS Congress; November 2017; Antalya, Turkey, 2017.Available from:. http://hivaids2017.org/bildiriozetleri.pdf
[13]
Yaylalı E, Erdogan ZM. HIV/AIDS incidence and prevalence estimated by mathematical modeling in Turkey, 2005-2030. Proceedings of the HIV/AIDS Congress; November 2018; Antalya, Turkey, 2017.Available from:. http://2018hivaids.org/2018-bildiri-kitabi. pdf
[14]
Dokuzoguz B, Korten V, Gökengin D, et al. Transmission route and reasons for HIV testing among recently diagnosed HIV patients in HIV-TR cohort, 2011-2012. J Int AIDS Soc 2014; 17(4)(Suppl. 3): 19595.
[http://dx.doi.org/10.7448/IAS.17.4.19595] [PMID: 25394100]
[15]
Sargin F, Yildiz D, Aydin OA, et al. Changes in HIV demographic patterns in a low prevalence population: no evidence of a shift towards men who have sex with men. Int J Infect Dis 2016; 48: 52-6.
[http://dx.doi.org/10.1016/j.ijid.2016.05.006] [PMID: 27173075]
[16]
Lunar MM, Vandamme AM, Tomažič J, et al. Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe. BMC Infect Dis 2015; 15: 65.
[http://dx.doi.org/10.1186/s12879-015-0802-6] [PMID: 25887543]
[17]
Nikolopoulos GK, Chanos S, Tsioptsias E, Hodges-Mameletzis I, Paraskeva D, Dedes N. HIV incidence among men who have sex with men at a community-based facility in Greece. Cent Eur J Public Health 2019; 27(1): 54-7.
[http://dx.doi.org/10.21101/cejph.a4856] [PMID: 30927398]
[18]
Bozicevic I, Handanagic S, Lepej SZ, Begovac J. The emerging and re-emerging human immunodeficiency virus epidemics in Europe. Clin Microbiol Infect 2013; 19(10): 917-29.
[http://dx.doi.org/10.1111/1469-0691.12313] [PMID: 24205884]
[19]
Tsantes A, Nikolopoulos G, Masgala A, Paraskeva D. Assessing the secular trends in the transmission of HIV in Greece. Sex Transm Infect 2005; 81(3): 230-2.
[http://dx.doi.org/10.1136/sti.2004.010975] [PMID: 15923291]
[20]
Pharris A, Quinten C, Tavoschi L, Spiteri G, Amato-Gauci AJ. Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: New HIV diagnoses still increasing in men who have sex with men. Euro Surveill 2015; 20(47)
[http://dx.doi.org/10.2807/1560-7917.ES.2015.20.47.30071] [PMID: 26625124]
[21]
Leelawiwat W, Rutvisuttinunt W, Arroyo M, et al. Increasing HIV-1 molecular complexity among men who have sex with men in Bangkok. AIDS Res Hum Retroviruses 2015; 31(4): 393-400.
[http://dx.doi.org/10.1089/aid.2014.0139] [PMID: 25366819]
[22]
Ferrer L, Loureiro E, Meulbroek M, et al. High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort. Sex Transm Infect 2016; 92(1): 70-5.
[http://dx.doi.org/10.1136/sextrans-2015-052042] [PMID: 26136507]
[23]
Meireles P, Lucas R, Carvalho C, et al. Incident risk factors as predictors of HIV seroconversion in the Lisbon cohort of men who have sex with men: first results, 2011-2014. Euro Surveill 2015; 20(14): 21091.
[http://dx.doi.org/10.2807/1560-7917.ES2015.20.14.21091] [PMID: 25884151]
[24]
Marcus U, Hickson F, Weatherburn P, Schmidt AJ, Network E. EMIS Network. Prevalence of HIV among MSM in Europe: comparison of self-reported diagnoses from a large scale internet survey and existing national estimates. BMC Public Health 2012; 12: 978.
[http://dx.doi.org/10.1186/1471-2458-12-978] [PMID: 23151263]
[25]
Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012; 380(9839): 367-77.
[http://dx.doi.org/10.1016/S0140-6736(12)60821-6] [PMID: 22819660]
[26]
Assi A, Abu Zaki S, Ghosn J, et al. Prevalence of HIV and other sexually transmitted infections and their association with sexual practices and substance use among 2238 MSM in Lebanon. Sci Rep 2019; 9(1): 15142.
[http://dx.doi.org/10.1038/s41598-019-51688-7] [PMID: 31641252]
[27]
Beyrer C, Sullivan P, Sanchez J, et al. The increase in global HIV epidemics in MSM. AIDS 2013; 27(17): 2665-78.
[http://dx.doi.org/10.1097/01.aids.0000432449.30239.fe] [PMID: 23842129]
[28]
90-90-90 An ambitious treatment target to help end the AIDS epidemic Joint United Nations Programme on HIV/AIDS (UNAIDS). JC2684 O 2014.Available at:. https://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf [February 10]
[29]
Raymond A, Hill A, Pozniak A. Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break points. J Int AIDS Soc 2014; 17(4)(Suppl. 3): 19507.
[http://dx.doi.org/10.7448/IAS.17.4.19507] [PMID: 25394016]
[30]
Levi J, Pozniak A, Heath K, Hill A. The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries. J Virus Erad 2018; 4(2): 80-90.
[PMID: 29682299]
[31]
Drew RS, Rice B, Rüütel K, et al. HIV continuum of care in Europe and Central Asia. HIV Med 2017; 18(7): 490-9.
[http://dx.doi.org/10.1111/hiv.12480] [PMID: 28117527]
[32]
Vourli G, Nikolopoulos G, Paparizos V, et al. Greek HIV Prevention Group. HIV cascade of care in Greece: Useful insights from additional stages. PLoS One 2018; 13(11) e0207355
[http://dx.doi.org/10.1371/journal.pone.0207355] [PMID: 30440000]
[33]
Ghalehkhani N, Farhoudi B, Gouya MM, et al. The HIV treatment cascade in people living with HIV in Iran in 2014: Mixed-method study to measure losses and reasons. Int J STD AIDS 2019; 30(13): 1257-64.
[http://dx.doi.org/10.1177/0956462419867573] [PMID: 31558135]
[34]
García-Deltoro M. Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis. AIDS Rev 2019; 21(2): 55-64.
[http://dx.doi.org/10.24875/AIDSRev.M19000027] [PMID: 31332395]
[35]
Boyd MA, Boffito M, Castagna A, Estrada V. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med 2019; 20(Suppl. 1): 3-11.
[http://dx.doi.org/10.1111/hiv.12708] [PMID: 30724450]
[36]
Venter WD, Ford N, Vitoria M, Stevens W. Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Curr Opin HIV AIDS 2017; 12(2): 117-22.
[http://dx.doi.org/10.1097/COH.0000000000000354] [PMID: 28134712]
[37]
Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373(9): 795-807.
[http://dx.doi.org/10.1056/NEJMoa1506816] [PMID: 26192873]
[38]
Danel C, Moh R, Gabillard D, et al. TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373(9): 808-22.
[http://dx.doi.org/10.1056/NEJMoa1507198] [PMID: 26193126]
[39]
Bavinton BR, Jin F, Prestage G, et al. Opposites Attract Study Group. The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. BMC Public Health 2014; 14: 917.
[http://dx.doi.org/10.1186/1471-2458-14-917] [PMID: 25190360]
[40]
Rodger AJ, Cambiano V, Bruun T, et al. PARTNER Study Group. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA 2016; 316(2): 171-81.
[http://dx.doi.org/10.1001/jama.2016.5148] [PMID: 27404185]
[41]
Rodger AJ, Cambiano V, Bruun T, et al. PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. Lancet 2019; 393(10189): 2428-38.
[http://dx.doi.org/10.1016/S0140-6736(19)30418-0] [PMID: 31056293]
[42]
Mete B, Gunduz A, Bolukcu S, et al. HIV care in Istanbul, Turkey: How far is it from the UNAIDS 90-90-90 targets? Int J STD AIDS 2019; 30(13): 1298-303.
[http://dx.doi.org/10.1177/0956462419866342] [PMID: 31726930]
[43]
Kadam AV, Bembalkar SC, Panchal NU, Mamulwar MS, Shete AV, Godbole SV. Persons living with HIV continue to present late for care: A trend analysis from 2011 to 2015. Indian J Sex Transm Dis AIDS 2019; 40(2): 133-8.
[http://dx.doi.org/10.4103/ijstd.IJSTD_5_18] [PMID: 31922103]
[44]
Lakhe NA, Diallo Mbaye K, Sylla K, Ndour CT. HIV screening in men and women in Senegal: coverage and associated factors; analysis of the 2017 demographic and health survey. BMC Infect Dis 2019; 20(1): 1.
[http://dx.doi.org/10.1186/s12879-019-4717-5] [PMID: 31892320]
[45]
Williams LD, Korobchuk A, Pavlitina E, et al. Experiences of Stigma and Support Reported by Participants in a Network Intervention to Reduce HIV Transmission in Athens, Greece; Odessa, Ukraine; and Chicago, Illinois. AIDS Behav 2019; 23(5): 1210-24.
[http://dx.doi.org/10.1007/s10461-019-02402-1] [PMID: 30680540]
[46]
Korten V, Gökengin D, Fincanci M, et al. Outcomes of initial antiretroviral treatment (ART) among recently diagnosed HIV patients in HIV-TR cohort, 2011-2012. J Int AIDS Soc 2014; 17(4)(Suppl. 3): 19678.
[http://dx.doi.org/10.7448/IAS.17.4.19678] [PMID: 25397428]
[47]
Mårdh O, Quinten C, Kuchukhidze G, et al. On Behalf Of The Ecdc/Who Hiv Surveillance Network. HIV among women in the WHO European Region - epidemiological trends and predictors of late diagnosis, 2009-2018. Euro Surveill 2019; 24(48) 1900696
[http://dx.doi.org/10.2807/1560-7917.ES.2019.24.48.1900696] [PMID: 31796153]
[48]
Elliott T, Sanders EJ, Doherty M, et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. J Int AIDS Soc 2019; 22(12) e25419
[http://dx.doi.org/10.1002/jia2.25419] [PMID: 31850686]
[49]
Wejnert C, Prejean J, Hoots B, Hall HI, McCray E, Mermin J. NHBS Study Group. Prevalence of Missed Opportunities for HIV Testing Among Persons Unaware of Their Infection. JAMA 2018; 319(24): 2555-7.
[http://dx.doi.org/10.1001/jama.2018.7611] [PMID: 29946714]
[50]
Lhopitallier L, Moulin E, Hugli O, Cavassini M, Darling KEA. Missed opportunities for HIV testing among patients newly presenting for HIV care at a Swiss university hospital: a retrospective analysis. BMJ Open 2018; 8(6) e019806
[http://dx.doi.org/10.1136/bmjopen-2017-019806] [PMID: 29895647]
[52]
Gokengin D, Oprea C, Begovac J, et al. HIV care in Central and Eastern Europe: How close are we to the target? Int J Infect Dis 2018; 70: 121-30.
[http://dx.doi.org/10.1016/j.ijid.2018.03.007] [PMID: 29550449]
[53]
METE B. Antiretroviral Therapy. Turkiye Klinikleri J Inf Dis-Special Topics 2019; 9(1): 101-7.
[54]
Kara E, İnkaya AC, Aydın Haklı D, Demirkan K, Ünal S. Polypharmacy and drug-related problems among people living with HIV/AIDS: a single-center experience. Turk J Med Sci 2019; 49(1): 222-9.
[http://dx.doi.org/10.3906/sag-1807-295] [PMID: 30761883]
[55]
Khan K, Khan AH, Sulaiman SA, Soo CT, Akhtar A. Adverse Drug Reactions in HIV/AIDS Patients at a Tertiary Care Hospital in Penang, Malaysia. Jpn J Infect Dis 2016; 69(1): 56-9.
[http://dx.doi.org/10.7883/yoken.JJID.2014.246] [PMID: 26073728]
[56]
Yildiz Sevgi D, Gunduz A, Altuntas Aydin O, et al. Adherence to Antiretroviral Therapy in Turkey: Results from the ACTHIV-IST Study Group. AIDS Res Hum Retroviruses 2017; 33(12): 1192-8.
[http://dx.doi.org/10.1089/aid.2016.0266] [PMID: 28854809]
[57]
Ceylan E, Koç A, İnkaya AC, Ünal S. Determination of medication adherence and related factors among people living with HIV/AIDS in a Turkish university hospital. Turk J Med Sci 2019; 49(1): 198-205.
[http://dx.doi.org/10.3906/sag-1802-137] [PMID: 30764598]
[58]
McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ 2013; 91(5): 377-385E.
[http://dx.doi.org/10.2471/BLT.12.112946] [PMID: 23678201]
[59]
Tanser F, Bärnighausen T, Vandormael A, Dobra A. HIV treatment cascade in migrants and mobile populations. Curr Opin HIV AIDS 2015; 10(6): 430-8.
[http://dx.doi.org/10.1097/COH.0000000000000192] [PMID: 26352396]
[60]
Camlin CS, Charlebois ED. Mobility and its Effects on HIV Acquisition and Treatment Engagement: Recent Theoretical and Empirical Advances. Curr HIV/AIDS Rep 2019; 16(4): 314-23.
[http://dx.doi.org/10.1007/s11904-019-00457-2] [PMID: 31256348]
[61]
Ergönül Ö, Tülek N, Kayı I, Irmak H, Erdem O, Dara M. Profiling infectious diseases in Turkey after the influx of 3.5 million Syrian refugees. Clin Microbiol Infect 2020; 26(3): 307-12.
[http://dx.doi.org/10.1016/j.cmi.2019.06.022] [PMID: 31284037]
[62]
İnkaya AC, Örgül G, Halis N, et al. Perinatal outcomes of 25 hiv-infected pregnant women: hacettepe university experience. J Turk Ger Gynecol Assoc 2019. Epub ahead of print
[http://dx.doi.org/10.4274/jtgga.galenos.2019.2019.0033] [PMID: 31564083]
[63]
Sahin ARSA, Gunduz A, Aktemur A, Kes-Uzun N. HIV seropositivity in a penal institution in Turkey: A cross-sectional study - Turkish. Klimik Derg 2018; 31: 132-4.
[http://dx.doi.org/10.5152/kd.2018.31]
[64]
Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016; 388(10049): 1089-102.
[http://dx.doi.org/10.1016/S0140-6736(16)30466-4] [PMID: 27427453]
[65]
Ganesan M, Poluektova LY, Kharbanda KK, Osna NA. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J Gastroenterol 2019; 25(4): 398-410.
[http://dx.doi.org/10.3748/wjg.v25.i4.398] [PMID: 30700937]
[66]
Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N. An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother 2017; 18(16): 1691-702.
[PMID: 29081251]
[67]
Desikan P, Khan Z. Prevalence of hepatitis B and hepatitis C virus co-infection in India: A systematic review and meta-analysis. Indian J Med Microbiol 2017; 35(3): 332-9.
[http://dx.doi.org/10.4103/ijmm.IJMM_17_257] [PMID: 29063876]
[68]
Karaosmanoglu HKMB. Serological profiles of HBV among HIV-infected patients in Istanbul, Turkey. Int J Clinical & Case 2018; 2: 44-7.
[69]
Altuntas Aydin o YM, Karaosmanoglu HK, et al. Low Prevalence of Hepatitis C Virus Infection Among HIV-Positive Patients: Data From a Large-Scale Cohort Study in Istanbul, Turkey. Hepat Mon 2014; 14 e18128.
[71]
Akhtar A, Khan AH, Sulaiman SA, Soo CT, Khan K. HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia. J Med Virol 2016; 88(3): 455-60.
[http://dx.doi.org/10.1002/jmv.24347] [PMID: 26255632]
[72]
Sayan M, Ozguler M, Yildirim FS, et al. Molecular Determining of HIV-1 with the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections. Balkan Med J 2020; 37: 125-30.
[http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2019.5.89]
[73]
Qadir MI. Hepatitis in AIDS patients. Rev Med Virol 2018; 28(1)
[http://dx.doi.org/10.1002/rmv.1956] [PMID: 29027728]
[74]
Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PLoS One 2016; 11(3) e0151946
[http://dx.doi.org/10.1371/journal.pone.0151946] [PMID: 27031352]
[75]
Aydin OA, Karaosmanoğlu HK, Sayan M, İnce ER, Nazlıcan Ö. Seroprevalence and risk factors of syphilis among HIV/AIDS patients in Istanbul, Turkey. Cent Eur J Public Health 2015; 23(1): 65-8.
[http://dx.doi.org/10.21101/cejph.a4001] [PMID: 26036101]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 4
Year: 2020
Published on: 08 September, 2020
Page: [258 - 266]
Pages: 9
DOI: 10.2174/1570162X18666200427223823
Price: $65

Article Metrics

PDF: 31
HTML: 1